These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 33545022)

  • 21. Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: A phase 3 randomized trial.
    Cannon K; Cardona JF; Yacisin K; Thompson A; Belanger TJ; Lee DY; Peng Y; Moyer L; Ginis J; Gruber WC; Scott DA; Watson W
    Vaccine; 2023 Mar; 41(13):2137-2146. PubMed ID: 36828719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 20-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults.
    Shirley M
    Drugs; 2022 Jun; 82(9):989-999. PubMed ID: 35793027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase 3 randomized study to evaluate safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in healthy Japanese infants.
    Ishihara Y; Fukazawa M; Enomoto S; de Solom R; Yamaji M; Kline M; Aizawa M; Peng Y; Kogawara O; Giardina PC; Tamimi N; Gruber WC; Watson W
    Int J Infect Dis; 2024 Apr; 141():106942. PubMed ID: 38242195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mathematical modeling of pneumococcal transmission dynamics in response to PCV13 infant vaccination in Germany predicts increasing IPD burden due to serotypes included in next-generation PCVs.
    Horn M; Theilacker C; Sprenger R; von Eiff C; Mahar E; Schiffner-Rohe J; Pletz MW; van der Linden M; Scholz M
    PLoS One; 2023; 18(2):e0281261. PubMed ID: 36791091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH).
    Song JY; Chang CJ; Andrews C; Diez-Domingo J; Oh MD; Dagan R; Hartzel J; Pedley A; Li J; Sterling T; Tamms G; Chiarappa JA; Lutkiewicz J; Musey L; Tu Y; Buchwald UK;
    Vaccine; 2021 Oct; 39(43):6422-6436. PubMed ID: 34489128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults ≥65 years old.
    Fitz-Patrick D; Young M; Yacisin K; McElwee K; Belanger T; Belanger K; Peng Y; Lee DY; Gruber WC; Scott DA; Watson W
    Vaccine; 2023 Jun; 41(28):4190-4198. PubMed ID: 37244809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.
    Platt H; Omole T; Cardona J; Fraser NJ; Mularski RA; Andrews C; Daboul N; Gallagher N; Sapre A; Li J; Polis A; Fernsler D; Tamms G; Xu W; Murphy R; Skinner J; Joyce J; Musey L
    Lancet Infect Dis; 2023 Feb; 23(2):233-246. PubMed ID: 36116461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1).
    Martinon-Torres F; Wysocki J; Szenborn L; Carmona-Martinez A; Poder A; Dagan R; Richmond P; Gilbert C; Trudel MC; Flores S; Lupinacci R; McFetridge R; Wiedmann RT; Chen Q; Gerrits H; Banniettis N; Musey L; Bickham K; Kaminski J;
    Vaccine; 2023 May; 41(21):3387-3398. PubMed ID: 37105892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults.
    Stacey HL; Rosen J; Peterson JT; Williams-Diaz A; Gakhar V; Sterling TM; Acosta CJ; Nolan KM; Li J; Pedley A; Benner P; Abeygunawardana C; Kosinski M; Smith WJ; Pujar H; Musey LK
    Hum Vaccin Immunother; 2019; 15(3):530-539. PubMed ID: 30648919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV.
    Wilck M; Barnabas S; Chokephaibulkit K; Violari A; Kosalaraksa P; Yesypenko S; Chukhalova I; Dagan R; Richmond P; Mikviman E; Morgan L; Feemster K; Lupinacci R; Chiarappa J; Madhi SA; Bickham K; Musey L;
    AIDS; 2023 Jul; 37(8):1227-1237. PubMed ID: 36939067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A phase III study (V114-033).
    Suzuki H; Fujita H; Iwai K; Kuroki H; Taniyama K; Shizuya T; Kishino H; Igarashi R; Shirakawa M; Sawata M
    Vaccine; 2023 Jul; 41(34):4933-4940. PubMed ID: 37344262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial.
    Platt HL; Bruno C; Buntinx E; Pelayo E; Garcia-Huidobro D; Barranco-Santana EA; Sjoberg F; Song JY; Grijalva CG; Orenstein WA; Morgan L; Fernsler D; Xu W; Waleed M; Li J; Buchwald UK;
    Lancet Infect Dis; 2024 Jul; ():. PubMed ID: 38964361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States.
    Huang L; Wasserman M; Grant L; Farkouh R; Snow V; Arguedas A; Chilson E; Sato R; Perdrizet J
    Vaccine; 2022 Aug; 40(33):4700-4708. PubMed ID: 35753839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study.
    Quinn CT; Wiedmann RT; Jarovsky D; Lopez-Medina E; Rodriguez HM; Papa M; Boggio G; Shou Q; Dagan R; Richmond P; Feemster K; McFetridge R; Tamms G; Lupinacci R; Musey L; Bickham K
    Blood Adv; 2023 Feb; 7(3):414-421. PubMed ID: 36383730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN).
    Banniettis N; Wysocki J; Szenborn L; Phongsamart W; Pitisuttithum P; Rämet M; Richmond P; Shi Y; Dagan R; Good L; Papa M; Lupinacci R; McFetridge R; Tamms G; Churchill C; Musey L; Bickham K;
    Vaccine; 2022 Oct; 40(44):6315-6325. PubMed ID: 36150974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Streptococcus pneumoniae serotype 15B polysaccharide conjugate elicits a cross-functional immune response against serotype 15C but not 15A.
    Hao L; Kuttel MM; Ravenscroft N; Thompson A; Prasad AK; Gangolli S; Tan C; Cooper D; Watson W; Liberator P; Pride MW; Jansen KU; Anderson AS; Scully IL
    Vaccine; 2022 Aug; 40(33):4872-4880. PubMed ID: 35810060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in Japanese healthy adults: A Phase I study.
    Haranaka M; Yono M; Kishino H; Igarashi R; Oshima N; Sawata M; Platt HL
    Hum Vaccin Immunother; 2023 Aug; 19(2):2228162. PubMed ID: 37389808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
    Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
    Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of a 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A Phase I study (V114-028).
    Ishihara Y; Kuroki H; Hidaka H; Iwai K; Wan K; Shirakawa M; Sawata M
    Hum Vaccin Immunother; 2023 Dec; 19(1):2180973. PubMed ID: 36882898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.